MedTrace Logo

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

NCT03590652 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-10-21

No results posted yet for this study

Summary

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

Conditions

Interventions

DRUG

Ixazomib

4mg PO days 1,8,15 on 28-day cycle

DRUG

Pomalidomide

4mg days PO 1-21/28 days

DRUG

Dexamethasone

40mg\*\* PO weekly \*\* starting dose for age \>75 may be 20mg

DRUG

Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)

1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly

Sponsors & Collaborators

Principal Investigators

  • Caitlin Costello, MD · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-17
Primary Completion
2025-07-02
Completion
2025-07-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03590652 on ClinicalTrials.gov